Neuropsychopharmacology Reports最新文献_第8页

Drinking behavior patterns may be associated with persistent depressive symptoms after alcohol abstinence in alcohol use disorder. 饮酒行为模式可能与酒精使用障碍患者戒酒后的持续抑郁症状有关。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-06-01 Epub Date: 2024-03-11 DOI: 10.1002/npr2.12429

Kazuhiro Kurihara, Hotaka Shinzato, Yoshikazu Takaesu, Tsuyoshi Kondo

{"title":"Drinking behavior patterns may be associated with persistent depressive symptoms after alcohol abstinence in alcohol use disorder.","authors":"Kazuhiro Kurihara, Hotaka Shinzato, Yoshikazu Takaesu, Tsuyoshi Kondo","doi":"10.1002/npr2.12429","DOIUrl":"10.1002/npr2.12429","url":null,"abstract":"Aim: This study examined the association between drinking behavior patterns and depressive symptoms after alcohol abstinence in patients with alcohol use disorder (AUD).Method: We recruited 102 AUD inpatients with baseline depressive symptoms, indicated by scores ≥6 on the Quick Inventory of Depressive Symptomatology Self-Report Japanese Version (QIDS-SR-J) pre-detoxification. Post-4-week abstinence, remission was defined as QIDS-SR-J scores <6. Patients were classified into remitted (n = 51) and persistent (n = 51) groups. Comparative analyses were conducted using patient profiles and the Drinking Behavior Pattern 20-item Questionnaire (DBP-20). Logistic regression identified factors related to post-abstinence persistent depression. Receiver operating characteristic curve analysis determined DBP-20 cutoff scores differentiating between persistent and remitted depression.Results: The persistent group exhibited higher scores in the DBP-20 \"coping with negative affect\" subscale. Logistic regression showed low education, unemployment, and using alcohol for coping as significant factors for persistent depression. Conversely, an automatic drinking pattern indicated natural remission post-abstinence. A subscale score of ≥8 in alcohol use for coping, especially among unemployed patients, predicted persistent depression (sensitivity 86.8%, positive predictive value 73.3%).Conclusion: Unemployed patients with AUD using alcohol to cope with negative affect may experience residual depression even after detoxification. In contrast, patients with AUD with predominantly automatic drinking behavior may exhibit natural remission post-abstinence.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"381-388"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects. 寻找重大精神障碍患者脑脊液生物标记物：多重免疫测定的发现和近距离延伸测定的前景。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-06-01 Epub Date: 2024-04-30 DOI: 10.1002/npr2.12439

Shinsuke Hidese

{"title":"Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects.","authors":"Shinsuke Hidese","doi":"10.1002/npr2.12439","DOIUrl":"10.1002/npr2.12439","url":null,"abstract":"Multiplex immunoassays have been developed to detect multiple proteins simultaneously and are used to search for biomarkers, including those present in major psychiatric disorders. This study aimed to review multiplex immunoassay studies on cerebrospinal fluid (CSF) biomarkers in patients with schizophrenia, bipolar disorder (BD), and major depressive disorder (MDD) and examine future research directions using improved proteomic techniques. According to the results of previous multiplex immunoassay studies, increased CSF IFN-β, IL-8, MCP-2, MMP-2, PAI-1, sICAM-1, and sVCAM-1 and decreased CSF ACE, APP, fibrinogen, and GDNF were observed in patients with schizophrenia, while CSF HGF and S100B were positively correlated with psychotic symptom and CSF IL-11, IL-29/IFN-λ1, and TSLP were negatively correlated. Increased CSF IFN-β and IL-1β and decreased CSF Aβ42, APP, IL-6, and NCAM-1 were observed, while CSF S100B was positively correlated with manic symptom in patients with BD. Increased CSF IL-4, MCP-1, MIP-1β, and MMP-2 were observed in patients with MDD, while CSF HGF and MMP-2 were positively correlated with depressive symptom and CSF IL-15 and MCP-1 were negatively correlated. However, signal cross-talk and cross-reactivity problems have been observed in previous studies using multiplex immunoassay. The proximity extension assay can be used to overcome cross-reactivity and enable ultrasensitive multiplexed detection and quantification of more than 1000 target proteins. However, proteomic studies using proximity extension assay technology in patients with schizophrenia, BD, or MDD are still scarce. Therefore, future high-quality proteomic studies are required to identify CSF biomarkers for larger sets of target proteins in patients with major psychiatric disorders.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"314-320"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140869197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A systematic review of the beneficial effects of prebiotics, probiotics, and synbiotics on ADHD. 关于益生元、益生菌和合成益生元对多动症有益影响的系统性综述。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-06-01 Epub Date: 2024-04-16 DOI: 10.1002/npr2.12437

Pooneh Allahyari, Saheb Abbas Torki, Bahareh Aminnezhad Kavkani, Zahra Mahmoudi, Mohadeseh Sadat Mousavi Hoseini, Mahdi Moradi, Farkhondeh Alami, Mohammad Keshavarz Mohammadian, Samira Bahoo Sele Bani, Khadijeh Abbasi Mobarakeh, Hanieh Shafaei, Sara Khoshdooz, Azadeh Hajipour, Saeid Doaei, Maryam Gholamalizadeh

{"title":"A systematic review of the beneficial effects of prebiotics, probiotics, and synbiotics on ADHD.","authors":"Pooneh Allahyari, Saheb Abbas Torki, Bahareh Aminnezhad Kavkani, Zahra Mahmoudi, Mohadeseh Sadat Mousavi Hoseini, Mahdi Moradi, Farkhondeh Alami, Mohammad Keshavarz Mohammadian, Samira Bahoo Sele Bani, Khadijeh Abbasi Mobarakeh, Hanieh Shafaei, Sara Khoshdooz, Azadeh Hajipour, Saeid Doaei, Maryam Gholamalizadeh","doi":"10.1002/npr2.12437","DOIUrl":"10.1002/npr2.12437","url":null,"abstract":"Background: Children with attention deficit hyperactivity disorder (ADHD) may benefit from probiotics and prebiotics, but the effects are unclear. To determine whether probiotics and prebiotics affect children with ADHD, a systematic review was conducted.Methods: The present systematic review analyzed cohort studies and randomized controlled trials that examined whether prebiotics and probiotics are associated with ADHD. Seven randomized controlled trials and two cohort studies met our inclusion criteria.Results: Research on Lactobacillus rhamnosus GG (LGG) probiotic supplementation showed that children with ADHD had better emotional, physical, social, and school functioning, and a higher health-related quality of life compared to the placebo group. The studies also showed that Synbiotic 2000 reduces markers of intestinal and vascular inflammation in children with ADHD, in part through increasing SCFA levels.Conclusion: The use of probiotics and prebiotics as adjuvants therapy in patients with ADHD is beneficial. Further studies with longer duration, including more participants and a variety of age groups, and using various evaluation techniques such as in vivo observation are required to examine the effects of prebiotics and probiotics on ADHD.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"300-307"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-marketing surveillance of quetiapine fumarate extended-release tablets in patients with bipolar depression. 富马酸喹硫平缓释片在双相抑郁症患者中的上市后监测。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-06-01 Epub Date: 2024-04-30 DOI: 10.1002/npr2.12441

Taro Kishi, Nakao Iwata, Hiroyuki Irie, Masaru Aikawa

{"title":"Post-marketing surveillance of quetiapine fumarate extended-release tablets in patients with bipolar depression.","authors":"Taro Kishi, Nakao Iwata, Hiroyuki Irie, Masaru Aikawa","doi":"10.1002/npr2.12441","DOIUrl":"10.1002/npr2.12441","url":null,"abstract":"Aim: This study aimed to verify the real-world efficacy and safety of quetiapine fumarate extended-release tablets (Bipresso® 50 mg and 150 mg; marketing authorization holder is KYOWA Pharmaceutical Industry Co., Ltd., Osaka, Japan) in patients with bipolar depression.Methods: We performed a post-marketing surveillance with an observation period of 12 weeks.Results: In the safety analysis group (n = 345), adverse drug reactions (ADRs) occurred in 111 patients (32.17%). The most common ADRs (>1%) were somnolence in 55 patients (15.94%), akathisia in 11 (3.19%), dizziness in 10 (2.90%), weight increase in 6 (1.74%), thirst in 5 (1.45%), and hypersomnia, constipation, and nausea in 4 patients each (1.16%). The only severe ADR was one patient of suicidal ideation, and \"longer time since the onset of the first episode\" (p = 0.011) and \"presence of complications\" (p < 0.001) were identified as significant risk factors for the occurrence of ADRs. In the efficacy analysis group (n = 265), the average changes from baseline in the total Montgomery-Åsberg Depression Rating Scale (MADRS) score were -7.3 ± 8.8, -12.2 ± 10.7, -16.8 ± 12.7, and -13.2 ± 12.7 points after 4, 8, and 12 weeks, and at the last evaluation, respectively. The mean MADRS total score decrease had no significant association with maximum daily dose, diagnosis, and presence or absence of prior or concomitant treatment for bipolar disorder with mood stabilizers/antipsychotics/antidepressants.Conclusion: The efficacy of quetiapine fumarate extended-release tablets was confirmed in clinical practice, and no new safety concerns or risks were identified.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"424-436"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of intermittent subchronic MK-801 administration on dopamine synthesis capacity and responsiveness in the prefrontal cortex. 间歇性亚慢性 MK-801 给药对前额叶皮层多巴胺合成能力和反应能力的影响

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-06-01 Epub Date: 2024-02-20 DOI: 10.1002/npr2.12420

Kazuro Shibata, Kosuke Enomoto, Takahiro Tsutsumi, Hiroyuki Muraoka, Tatsu Fuwa, Masahiko Kawano, Jun Ishigooka, Ken Inada, Katsuji Nishimura, Hidehiro Oshibuchi

{"title":"Effect of intermittent subchronic MK-801 administration on dopamine synthesis capacity and responsiveness in the prefrontal cortex.","authors":"Kazuro Shibata, Kosuke Enomoto, Takahiro Tsutsumi, Hiroyuki Muraoka, Tatsu Fuwa, Masahiko Kawano, Jun Ishigooka, Ken Inada, Katsuji Nishimura, Hidehiro Oshibuchi","doi":"10.1002/npr2.12420","DOIUrl":"10.1002/npr2.12420","url":null,"abstract":"Aim: The therapeutic potential of N-methyl-D-aspartate glutamate receptor (NMDAR) antagonists, particularly ketamine, in mood disorders, is linked to their modulation of dopamine dynamics in the medial prefrontal cortex (mPFC). However, conflicting effects of distinct NMDAR antagonists, like ketamine and phencyclidine, on mPFC dopamine levels stem from variances in their receptor affinity profiles. This study investigates the impact of intermittent subchronic administration of an NMDAR antagonist on dopamine synthesis capacity and responsiveness within the mPFC, focusing on Dizocilpine (MK-801), a highly selective NMDAR antagonist.Methods: In vivo microdialysis and high-performance liquid chromatography assessed extracellular dopamine levels in the mPFC following subchronic MK-801 treatment. Locomotor activity was measured using a computed video tracking system.Results: Intermittent subchronic MK-801 administration, followed by a 24-h withdrawal, preserved both dopamine synthesis capacity and responsiveness to MK-801 challenge in the mPFC. However, altered locomotor activity was observed, deviating from previous findings indicating impaired dopamine synthesis and responsiveness in the mPFC with twice-daily subchronic NMDAR antagonist treatment.Conclusion: These findings offer crucial biochemical insights into the diverse impacts of NMDAR antagonists on dopamine dynamics and the distinct therapeutic mechanisms associated with ketamine in depression treatment. However, further investigation is imperative to pinpoint potential inconsistencies stemming from variances in drug type, dosage, or administration frequency.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"333-341"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139913155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in suicidal ideation during treatment among patients with major depressive disorder: A 6-month naturalistic follow-up study. 重度抑郁障碍患者在治疗期间自杀意念的变化：为期 6 个月的自然追踪研究。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-06-01 Epub Date: 2024-03-05 DOI: 10.1002/npr2.12428

Aoi Sato, Norio Sugawara, Yasushi Kawamata, Norio Yasui-Furukori

{"title":"Changes in suicidal ideation during treatment among patients with major depressive disorder: A 6-month naturalistic follow-up study.","authors":"Aoi Sato, Norio Sugawara, Yasushi Kawamata, Norio Yasui-Furukori","doi":"10.1002/npr2.12428","DOIUrl":"10.1002/npr2.12428","url":null,"abstract":"Aim: There is limited evidence regarding predictors of changes in suicidal ideation (SI) in patients with major depressive disorder (MDD). The objective of this study was to describe changes in SI over a 6-month period and identify their predictors from naturalistic observations of MDD patients.Methods: In the cross-sectional analysis, we examined 257 patients with MDD at the first-visit assessment. Among the patients, 119 who completed the 6-month assessment (completers) were included in the longitudinal analysis. For the evaluation of depressive symptoms, including SI, the Quick Inventory of Depressive Symptomatology-Japanese version was administered at both the first-visit and follow-up assessments. At baseline, we also administered the Japanese version of the Ten Item Personality Inventory to assess personality traits and the PRIME Screen-Revised to assess psychotic symptoms.Results: In the cross-sectional analysis of first-visit patients, 36.2% (93/257) exhibited SI. Among completers, 14.3% (17/119) had prolonged SI. Among the completers with SI at the first-visit assessment, 38.6% (17/44) had SI at the follow-up assessment (prolonged SI). In linear regression models including all completers, prolonged SI was positively associated with endorsement of suspiciousness/persecutory ideas and negatively associated with higher age.Conclusion: More than one-third of completers who had SI at the first-visit assessment experienced prolonged SI (SI at follow-up). Our findings can help clinicians predict the course of MDD by identifying associated demographic and clinical characteristics.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"371-380"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140039918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of the 12-item and 36-item versions of the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 using longitudinal data from community mental health outreach service users. 利用社区精神健康外展服务使用者的纵向数据，比较世界卫生组织残疾评估表（WHODAS）2.0 的 12 项和 36 项版本。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-06-01 Epub Date: 2024-03-11 DOI: 10.1002/npr2.12426

Mai Iwanaga, Sosei Yamaguchi, Sayaka Sato, Kaori Usui, Kiyoaki Nakanishi, Erisa Nishiuchi, Michiyo Shimodaira, Yugan So, Chiyo Fujii

{"title":"Comparison of the 12-item and 36-item versions of the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 using longitudinal data from community mental health outreach service users.","authors":"Mai Iwanaga, Sosei Yamaguchi, Sayaka Sato, Kaori Usui, Kiyoaki Nakanishi, Erisa Nishiuchi, Michiyo Shimodaira, Yugan So, Chiyo Fujii","doi":"10.1002/npr2.12426","DOIUrl":"10.1002/npr2.12426","url":null,"abstract":"Aim: This study aimed to compare the 12-item and 36-item versions of the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 using longitudinal data from community mental health outreach service users.Methods: Using data from Tokorozawa City mental health outreach service users in Japan, total and domain WHODAS-12 and WHODAS-36 scores were compared. First, we examined score-change differences by domain at the start of outreach services (T1) and 1 year later (T2) for each version. Next, we compared differences between the two versions using Pearson's correlation, Wilcoxon signed-rank test, and Bland-Altman analysis.Results: Among 20 participants, total scores and scores of some domains (i.e., cognition, getting along, life activities, and participation) were significantly lower at T2 than at T1 on both versions (p < 0.010). WHODAS-36 scores were significantly lower at T2 than at T1 for the self-care domain (p = 0.018). Except for self-care, strong correlations were found between scores from the two versions (p < 0.001). In the Wilcoxon signed-rank test and Bland-Altman analysis, we found significant differences between the scores of the two versions in the mobility, self-care, and participation domains. There were no significant differences in the distribution or systematic errors between the two versions in scores for the other domains or total score.Conclusion: We found strong positive correlations between WHODAS-12 and WHODAS-36 total scores with no statistical differences between them. For some domains, differences in distribution and systematic errors were found.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"457-463"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140102131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quantification of cytosine modifications in the aged mouse brain. 衰老小鼠脑内胞嘧啶修饰的定量分析。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-03-01 Epub Date: 2023-12-06 DOI: 10.1002/npr2.12396

Hiroko Sugawara, Akitoshi Date, Satoshi Fuke, Yutaka Nakachi, Tadafumi Kato, Minoru Narita, Miki Bundo, Kazuya Iwamoto

{"title":"Quantification of cytosine modifications in the aged mouse brain.","authors":"Hiroko Sugawara, Akitoshi Date, Satoshi Fuke, Yutaka Nakachi, Tadafumi Kato, Minoru Narita, Miki Bundo, Kazuya Iwamoto","doi":"10.1002/npr2.12396","DOIUrl":"10.1002/npr2.12396","url":null,"abstract":"Quantifying cytosine modifications in various brain regions provides important insights into the gene expression regulation and pathophysiology of neuropsychiatric disorders. In this study, we quantified 5-methylcytosine (5-mC), 5-hydroxymethylation (5-hmC), and 5-formylcytosine (5-fC) levels in five brain regions (the frontal lobe, cerebral cortical region without frontal lobe, hippocampus, basal ganglia, and the cerebellum) and the heart at three developmental periods (12, 48, and 101 weeks). We observed significant regional variations in cytosine modification. Notably, regional variations were generally maintained throughout development, suggesting that epigenetic regulation is unique to each brain region and remains relatively stable with age. The 5-mC and 5-hmC levels were positively correlated, although the extent of the correlations seemed to differ in different brain regions. On the contrary, 5-fC levels did not correlate with 5-mC or 5-hmC levels. Additionally, we observed an age-dependent decrease in 5-fC levels in the basal ganglia, suggesting a unique epigenetic regulation mechanism. Further high-resolution studies using animal models of neuropsychiatric disorders as well as postmortem brain evaluation are warranted.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"250-255"},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138499005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID-19 pandemic: A micro-narrative review. 在 COVID-19 大流行期间，长效注射用抗精神病药物作为精神分裂症的维持疗法：微观叙事回顾。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-03-01 Epub Date: 2024-01-06 DOI: 10.1002/npr2.12413

Yoshiyo Oguchi, Nobumi Miyake, Kumiko Ando

{"title":"Long-acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID-19 pandemic: A micro-narrative review.","authors":"Yoshiyo Oguchi, Nobumi Miyake, Kumiko Ando","doi":"10.1002/npr2.12413","DOIUrl":"10.1002/npr2.12413","url":null,"abstract":"The coronavirus disease pandemic has presented healthcare systems with unprecedented challenges globally and substantially impacted the management of chronic diseases such as schizophrenia. This narrative review highlights the usefulness of long-acting injectable antipsychotics (LAIs) as maintenance therapy for patients with schizophrenia during the pandemic. The analysis of relevant literature and psychiatric survey data revealed diverse trends in LAIs prescription and patient adherence with oral antipsychotics. Although some studies have reported a decrease in LAIs prescriptions owing to pandemic-related disruptions, others have suggested stable patient adherence with oral antipsychotics. Approximately 70% of Japanese psychiatrists reported an increase in schizophrenia relapse rates in a survey, underscoring the critical role of LAIs in maintaining therapeutic stability. The potential benefits of LAIs with extended dosing intervals have been highlighted, including improving oral medication adherence and reducing the frequency of hospital visits. In conclusion, this review emphasizes the continued need for uninterrupted LAIs therapy in conjunction with community and home-based care despite the disruptions caused by the coronavirus disease pandemic. Further development of LAIs maintenance therapy strategies considering the ongoing pandemic and potential future public health emergencies are required.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"34-41"},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139111110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. 一项多中心、单臂、开放标签的干预性研究，旨在了解精神分裂症或情感分裂症患者从既往的抗精神病药物转用布来匹唑期间的依从性。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-03-01 Epub Date: 2024-01-22 DOI: 10.1002/npr2.12416

Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi

{"title":"A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder.","authors":"Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi","doi":"10.1002/npr2.12416","DOIUrl":"10.1002/npr2.12416","url":null,"abstract":"The rate of medication persistence was examined in patients with schizophrenia or schizoaffective disorder during switching from previously administered antipsychotics to brexpiprazole, a new dopamine D2 receptor partial agonist. A multicenter, single-arm, open-label 24-week interventional study was conducted, consisting of two 12-week consecutive periods: an initial switch (by plateau cross-titration) with the subsequent period, followed by a second maintenance period. Prior antipsychotics were olanzapine or risperidone/paliperidone. The primary and secondary outcome measures were medication persistence rates after the first 12 weeks and changes from baseline in the Specific Levels of Functioning Scale (SLOF), Subjective Well-being under Neuroleptic drug treatment Short form (SWNS), and Positive and Negative Syndrome Scale (PANSS) scores, respectively. In total, 79 patients were administered brexpiprazole and the medication persistence rate at 12 weeks was 78.5%, which was significantly higher than the predefined threshold of 65%. Regarding the prior medication, the persistence rate at 12 weeks was 84.6% for olanzapine and 72.5% for risperidone/paliperidone. Significant improvements from baseline were observed in the SLOF, SWNS, and PANSS scores. There were no adverse events of concern. Thus, brexpiprazole appeared to be a suitable antipsychotic on switching from olanzapine, risperidone, or paliperidone.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"187-196"},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139521685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0